XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis

Eline Boons; Tatiane C. Nogueira; Tim Dierckx; Soraya Maria Menezes; Maarten Jacquemyn; Sharon Tamir; Yosef Landesman; Lourdes Farré; Achiléa Bittencourt; Keisuke Kataoka; Seishi Ogawa; Robert Snoeck; Graciela Andrei; Johan Van Weyenbergh; Dirk Daelemans

doi:10.1038/s41408-021-00409-3

XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis

Eline Boons, Tatiane C. Nogueira, Tim Dierckx, Soraya Maria Menezes, Maarten Jacquemyn, Sharon Tamir, Yosef Landesman, Lourdes Farré, Achiléa Bittencourt, Keisuke Kataoka, Seishi Ogawa, Robert Snoeck, Graciela Andrei, Johan Van Weyenbergh, Dirk Daelemans

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Article number	27
Journal	Blood cancer journal
Volume	11
Issue number	2
DOIs	https://doi.org/10.1038/s41408-021-00409-3
Publication status	Published - 2021 Feb
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-021-00409-3

Cite this

Boons, E., Nogueira, T. C., Dierckx, T., Menezes, S. M., Jacquemyn, M., Tamir, S., Landesman, Y., Farré, L., Bittencourt, A., Kataoka, K., Ogawa, S., Snoeck, R., Andrei, G., Van Weyenbergh, J., & Daelemans, D. (2021). XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood cancer journal, 11(2), [27]. https://doi.org/10.1038/s41408-021-00409-3

Boons, E, Nogueira, TC, Dierckx, T, Menezes, SM, Jacquemyn, M, Tamir, S, Landesman, Y, Farré, L, Bittencourt, A, Kataoka, K, Ogawa, S, Snoeck, R, Andrei, G, Van Weyenbergh, J & Daelemans, D 2021, 'XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis', Blood cancer journal, vol. 11, no. 2, 27. https://doi.org/10.1038/s41408-021-00409-3

@article{64c74f92b4974d8ba30ec76d4401ce36,

title = "XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis",

author = "Eline Boons and Nogueira, {Tatiane C.} and Tim Dierckx and Menezes, {Soraya Maria} and Maarten Jacquemyn and Sharon Tamir and Yosef Landesman and Lourdes Farr{\'e} and Achil{\'e}a Bittencourt and Keisuke Kataoka and Seishi Ogawa and Robert Snoeck and Graciela Andrei and {Van Weyenbergh}, Johan and Dirk Daelemans",

note = "Funding Information: We acknowledge the technical assistance of L. Bral, B. Massant, and E. Vanstreels and all the patients and healthy controls who donated blood samples for this study. E.B. and T.D. acknowledge a PhD grant from the FWO (Fonds Wetenschappelijk Onderzoek) formerly the IWT. J.V.W. acknowledges funding from FWO (grant G0D6817N) and KU Leuven (“Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden”). S.O. is supported by Grant-in-Aid from the Japan Agency for Medical Research and Development [JP119cm0106501h0004, JP119cm0106501h0004], Grant-in-Aid for Scientific Research (KAKENHI 15H05909).",

year = "2021",

month = feb,

doi = "10.1038/s41408-021-00409-3",

language = "English",

volume = "11",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis

AU - Boons, Eline

AU - Nogueira, Tatiane C.

AU - Dierckx, Tim

AU - Menezes, Soraya Maria

AU - Jacquemyn, Maarten

AU - Tamir, Sharon

AU - Landesman, Yosef

AU - Farré, Lourdes

AU - Bittencourt, Achiléa

AU - Kataoka, Keisuke

AU - Ogawa, Seishi

AU - Snoeck, Robert

AU - Andrei, Graciela

AU - Van Weyenbergh, Johan

AU - Daelemans, Dirk

N1 - Funding Information: We acknowledge the technical assistance of L. Bral, B. Massant, and E. Vanstreels and all the patients and healthy controls who donated blood samples for this study. E.B. and T.D. acknowledge a PhD grant from the FWO (Fonds Wetenschappelijk Onderzoek) formerly the IWT. J.V.W. acknowledges funding from FWO (grant G0D6817N) and KU Leuven (“Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden”). S.O. is supported by Grant-in-Aid from the Japan Agency for Medical Research and Development [JP119cm0106501h0004, JP119cm0106501h0004], Grant-in-Aid for Scientific Research (KAKENHI 15H05909).

PY - 2021/2

Y1 - 2021/2

UR - http://www.scopus.com/inward/record.url?scp=85100985190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100985190&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00409-3

DO - 10.1038/s41408-021-00409-3

M3 - Letter

C2 - 33563902

AN - SCOPUS:85100985190

SN - 2044-5385

VL - 11

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 2

M1 - 27

ER -

XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this